The research team, led by Xiaotian Huang, Jiaoyang Zheng, Yiwen Wang and Hao Chen of the Health Management Center at the Second Affiliated Hospital of Naval Medical University, confronted a methodological problem that has plagued earlier work in this field. Most previous studies comparing bone metabolism in diabetic patients with and without osteoporosis used comparison groups that could be contaminated by antiresorptive drugs. Patients labeled as having diabetes without osteoporosis may in fact have been receiving medications such as bisphosphonates or denosumab for other reasons, including bone metastases from cancer, and those drugs profoundly alter the very biomarkers researchers were trying to compare. The team therefore excluded anyone with bone metastasis and drew its comparison group exclusively from patients with no record of antiresorptive therapy.

The scale of the dataset gives the findings unusual weight. The researchers screened electronic health records of hospitalized patients with type 2 diabetes treated between 2021 and 2024, identifying 461 patients with a documented diagnosis of both diabetes and osteoporosis. From a pool of 21,181 patients with diabetes but no osteoporosis and no antiresorptive drug exposure, they selected a matched comparison group of 1,383 individuals using propensity score matching at a one-to-three ratio. Matching was performed on age and sex, which the authors describe as the two strongest confounders of bone metabolism given the data available. The procedure worked as intended: after matching, the standardized mean difference for both variables was exactly zero, with the combined cohort averaging 69.3 years of age and 15.2 percent male.

Against this carefully balanced backdrop, the team compared a panel of serum biomarkers that together sketch the state of bone remodeling and mineral metabolism. Parathyroid hormone, or PTH, stood out immediately. Patients with both diabetes and osteoporosis had a mean PTH concentration of 40.3 nanograms per liter, compared with 52.0 nanograms per liter in the matched diabetes-only group, a relative reduction of 22.6 percent that was highly statistically significant and carried a moderate effect size, with Cohen’s d of minus 0.434. Yet the authors are careful to frame this correctly: the median values in both groups fell within the laboratory reference range of 15 to 65 nanograms per liter, meaning the difference represents a shift within the normal spectrum rather than outright hormone deficiency.

The rest of the biomarker panel told a quieter story. Serum calcium was statistically higher in the osteoporosis group, at 2.21 versus 2.20 millimoles per liter, but the authors themselves flag that an absolute difference of one hundredth of a millimole per liter is unlikely to carry any clinical meaning. Bone turnover markers, the dynamic readouts of skeletal remodeling, showed no significant differences at all. Beta-C-terminal telopeptide of type I collagen, known as beta-CTX, a marker of bone resorption, was essentially identical between groups at 0.38 nanograms per milliliter. Osteocalcin, a marker of bone formation produced by osteoblasts, averaged 12.0 versus 11.0 nanograms per milliliter, a difference that did not reach statistical significance. Even 25-hydroxyvitamin D, the storage form of vitamin D that constrains PTH secretion, was statistically indistinguishable at 24.7 versus 22.8 nanograms per milliliter.

One secondary analysis added a layer of physiological nuance. In the diabetes-only group, glycated hemoglobin, or HbA1c, the standard measure of long-term blood sugar control, showed a moderate negative correlation with osteocalcin, with a correlation coefficient of minus 0.456. This relationship is well described in the literature: osteoblasts and the skeleton participate in energy metabolism, and poor glycemic control appears to suppress osteocalcin. In the combined diabetes and osteoporosis group, however, the correlation was much weaker, at minus 0.206, though still statistically significant. The attenuation suggests that in patients whose skeletons are already compromised by osteoporosis, the glucose-osteocalcin axis may be distorted or dominated by other forces, although a cross-sectional design cannot determine which way the causality runs.

What could explain suppressed PTH in patients whose bones are demonstrably weaker? The authors discuss two candidate mechanisms, both of which they emphasize remain unproven. The first involves altered sensitivity of the calcium-sensing receptor, or CaSR, the molecular thermostat on parathyroid cells that tunes hormone release according to circulating calcium. Advanced glycation end products, the sugar-damaged proteins that accumulate in diabetes, are one plausible influence on receptor behavior, and a shift in CaSR set-point could hold PTH lower even at normal calcium levels. The second is the concept of functional hypoparathyroidism, in which the glands are structurally intact but fail to mount an adequate hormonal response. Either mechanism would matter clinically, because PTH helps maintain bone remodeling balance, and an inappropriately low level could theoretically contribute to the skeletal fragility that defines diabetic bone disease.

The study’s limitations are candidly stated and worth understanding, because they define exactly what the finding does and does not prove. The entire population consisted of patients with type 2 diabetes, so the data cannot establish whether diabetes itself alters bone turnover relative to people without diabetes. Osteoporosis classification relied on diagnostic codes in the electronic health record rather than uniform dual-energy X-ray absorptiometry confirmation for every participant, and estimated glomerular filtration rate data were not incorporated into the analysis, even though declining kidney function is a well-known driver of elevated PTH and could confound the comparison. The design is cross-sectional, capturing a single moment in time, so it can document association but never causation. The authors call for future studies with confirmed bone mineral density measurements, renal function data, and longitudinal follow-up to test the CaSR and functional hypoparathyroidism hypotheses directly.

Why does this matter beyond the statistics? Diabetes doubles the burden of fracture in ways that bone mineral density scans often fail to capture, a phenomenon researchers call diabetic bone disease, in which the skeleton may look adequate on imaging but behaves as fragile tissue under stress. If suppressed PTH proves to be a genuine and mechanistically meaningful feature of this condition, it could eventually serve as a biomarker for identifying diabetic patients at heightened skeletal risk, or even suggest therapeutic angles, since PTH analogs such as teriparatide are already used to build bone in osteoporosis. The Shanghai team’s contribution is methodological as much as biological: by scrubbing antiresorptive drug confounders from the comparison group and matching rigorously on age and sex, they have produced one of the cleaner snapshots to date of bone metabolism in the diabetes-osteoporosis overlap, and the picture they captured, a 22.6 percent PTH reduction against an otherwise unremarkable panel, is a lead worth chasing.

For now, the practical takeaway for clinicians is one of calibrated caution. Both groups’ median PTH values sat comfortably within the normal range, bone turnover markers did not differ, and the calcium difference was trivially small, so no immediate change in screening or treatment practice follows from this single study. What the research does deliver is a sharpened hypothesis and a template for testing it. As the authors conclude, the mechanisms involving altered calcium-sensing receptor sensitivity or functional hypoparathyroidism remain unproven and require direct investigation. Given that hundreds of millions of people worldwide live with type 2 diabetes and that fragility fractures carry enormous costs in mortality and independence, even a modest hormonal clue about why diabetic bones fail deserves the longitudinal, density-confirmed follow-up studies the researchers now propose.

Subject of Research: Parathyroid hormone and calcium homeostasis in type 2 diabetes patients with osteoporosis

Article Title: Parathyroid hormone suppression and calcium homeostasis shift in type 2 diabetes with osteoporosis: a propensity score-matched cross-sectional study

Article References: Huang, X., Zheng, J., Wang, Y., & Chen, H. (2026). Parathyroid hormone suppression and calcium homeostasis shift in type 2 diabetes with osteoporosis: a propensity score-matched cross-sectional study. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02549-8

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02549-8

Keywords: type 2 diabetes, osteoporosis, parathyroid hormone, bone turnover markers, calcium homeostasis, propensity score matching, cross-sectional study, vitamin D, osteocalcin, beta-CTX, calcium-sensing receptor, diabetic bone disease

The calcium-sensing receptor, or CaSR, was first cloned from bovine parathyroid glands and has long been recognised as a central guardian of calcium homeostasis. It sits in the cell membrane and detects even small fluctuations in extracellular calcium, triggering intracellular signalling cascades that keep blood calcium within a narrow, life-sustaining range. Although the liver is not a calciotropic organ, calcium signalling within hepatocytes influences glucose and lipid metabolism, bile secretion, mitochondrial activity, and fundamental cellular processes such as growth, differentiation, movement and programmed cell death. Disturbances in intracellular calcium have even been implicated in the progression of non-alcoholic fatty liver disease towards liver cancer, and CaSR has been linked to cholestasis, ischemia-reperfusion injury, insulin resistance and genetic susceptibility to hepatocellular carcinoma.

What makes CaSR particularly intriguing in cancer biology is its dual personality. In some tumours, including parathyroid and gastrointestinal cancers, the receptor appears to restrain growth and act as a tumour suppressor. In others, such as intrahepatic cholangiocarcinoma, breast cancer, osteosarcoma and Leydig cell tumours, CaSR activation instead promotes proliferation and metastatic behaviour. Genetic polymorphisms in the CaSR gene, particularly at the rs17251221 locus, have been shown to influence susceptibility to hepatocellular carcinoma and treatment outcomes. Yet the precise mechanisms by which the receptor operates in the most common form of primary liver cancer had remained poorly characterised, leaving an important gap in understanding that the new study set out to fill.

The stakes are considerable. Hepatocellular carcinoma accounts for roughly ninety percent of primary liver cancers, and liver cancer overall ranks as the sixth most commonly diagnosed malignancy and the third leading cause of cancer-related death worldwide. Patients diagnosed at an early stage can benefit from surgical resection, but those presenting with intermediate or advanced disease typically rely on chemotherapy or immunotherapy regimens whose clinical benefits remain constrained. Long-term survival is limited for a substantial proportion of patients, and the restricted array of validated therapeutic targets has made the search for new strategies an urgent medical priority.

In the new research, the team first confirmed that CaSR is present in two widely used human hepatocellular carcinoma cell lines, HepG2 and SMMC-7721, using immunofluorescence microscopy, quantitative reverse transcription PCR and Western blotting. Notably, SMMC-7721 cells expressed significantly higher levels of the receptor protein than HepG2 cells. The researchers then pharmacologically inhibited the receptor with NPS-2143, a well-characterised negative allosteric modulator of CaSR, and measured the consequences across a battery of functional assays. The results were striking: NPS-2143 reduced the proliferation of both cell lines in a concentration-dependent manner, with effects becoming particularly pronounced at 48 and 72 hours after treatment. The drug also lowered expression of PCNA, a proliferation marker, alongside reducing CaSR mRNA and protein levels.

Beyond proliferation, the researchers examined whether CaSR blockade could blunt the metastatic machinery of liver cancer cells, a critical question given that metastasis drives recurrence and poor outcomes in hepatocellular carcinoma. Using Transwell migration and invasion assays, they showed that treated cells migrated and invaded far less efficiently than untreated controls. At the molecular level, the expression of MMP-2 and MMP-9, matrix metalloproteinases that remodel the extracellular matrix and enable cells to breach tissue barriers, dropped significantly after NPS-2143 exposure. These findings suggest that CaSR supports the invasive potential of hepatocellular carcinoma cells at least partly by sustaining the production of these matrix-degrading enzymes.

The study also uncovered a pro-death effect. Flow cytometric analysis using Annexin V and propidium iodide staining revealed a marked increase in apoptotic cells after 24 hours of NPS-2143 treatment. Western blotting illuminated the underlying mechanism: the anti-apoptotic protein Bcl-2 was downregulated, while the pro-apoptotic protein Bax and cleaved caspase-3, the executioner enzyme of programmed cell death, were upregulated. This coordinated shift in the balance of apoptotic regulators indicates that blocking CaSR actively pushes liver cancer cells towards self-destruction rather than merely slowing their division.

To trace the signalling pathways responsible, the researchers turned their attention to the mitogen-activated protein kinases, or MAPKs, which govern proliferation, apoptosis, migration and survival in cancer. NPS-2143 treatment increased the phosphorylation of p38 MAPK, a pathway often associated with apoptotic signalling and tumour growth suppression, while simultaneously reducing the phosphorylation of ERK1/2, a cascade frequently hijacked by cancers to drive proliferation and invasion. Total levels of both proteins were unaffected, pointing to a specific change in pathway activation rather than protein abundance. The team then confirmed these results genetically: silencing CaSR with siRNA reproduced every pharmacological effect, curbing growth, migration and invasion while raising apoptotic rates and producing the same p38 and ERK1/2 phosphorylation changes.

Crucially, the anti-tumour effects extended into living animals. In female BALB/c nude mice bearing HepG2 xenografts, intraperitoneal injection of NPS-2143 at 10 micromoles per kilogram every 48 hours for 12 days significantly reduced tumour size and weight compared with vehicle controls, without any measurable loss of body weight. Immunohistochemistry of excised tumours showed reduced CaSR immunoreactivity and a sharp decline in Ki67 staining, indicating diminished cell division. Western blotting of tumour tissue mirrored the in vitro findings, with increased p-p38 and Bax and decreased p-ERK, MMP-9 and Bcl-2. Because NPS-2143 is primarily a functional antagonist rather than a transcriptional inhibitor, the authors interpret the reduced CaSR expression after treatment as a secondary feedback change rather than direct repression of the gene. To address the influence of sex, since hepatocellular carcinoma occurs more frequently in males, an independent experiment using Huh7 cells in male nude mice reproduced the tumour-shrinking effect, strengthening confidence in the result across cell lines and sexes.

The authors are careful to acknowledge the limitations of their work. Two cell lines cannot capture the full molecular diversity of hepatocellular carcinoma, the animal cohorts were modest in size, and immunodeficient mice cannot recapitulate the complex immune microenvironment of human liver cancer. Potential off-target interactions of NPS-2143 also cannot be entirely dismissed, and CRISPR-based knockout experiments would provide firmer genetic validation. Nevertheless, the convergence of pharmacological and genetic evidence, in vitro and in vivo, paints a coherent picture: CaSR supports the proliferation, motility and survival of hepatocellular carcinoma cells through ERK1/2 and p38 MAPK signalling, and its blockade reverses these malignant behaviours. If future studies in immunocompetent models and patient-derived systems confirm these findings, drugs that silence this calcium sensor could open a genuinely new front against one of the world’s deadliest cancers.

Subject of Research: The role of the calcium-sensing receptor in hepatocellular carcinoma progression and its inhibition as a potential therapy

Article Title: Inhibition of Calcium‐Sensing Receptor Suppresses Malignant Behaviours of Human Hepatocellular Carcinoma

Article References: Liu, T., Xu, W., Gao, Q., Ngwa Adeline, N., Yang, Q., He, D., Tao, Y., Sun, J., Gu, J., Shi, H., Aschner, M., Ye, Y., Chen, J., & Lu, R. (2026). Inhibition of Calcium‐Sensing Receptor Suppresses Malignant Behaviours of Human Hepatocellular Carcinoma. Journal of Cellular and Molecular Medicine, 30(19), Article e71389. https://doi.org/10.1111/jcmm.71389

Image Credits: AI Generated

DOI: 10.1111/jcmm.71389

Keywords: calcium-sensing receptor, hepatocellular carcinoma, liver cancer, NPS-2143, MAPK signalling, p38 MAPK, ERK1/2, apoptosis, cell migration, xenograft model, MMP-9, therapeutic target